Eveline P. Mauser-Bunschoten, MD, PhD; Marjolein Damen, MD; Henk W. Reesink, MD, PhD; Goris Roosendaal, MD; Robert A.F.M. Chamuleau, MD, PhD; H. Marijke van den Berg, MD, PhD
To evaluate the risk for development of antibodies to factor VIII (factor VIII inhibitors) during and after interferon therapy in patients with hemophilia A and chronic hepatitis C infection.
Patients were divided into two treatment groups and an untreated control group. Test results from the two treatment groups were compared with those from the control group.
3 clinical centers in the Netherlands.
35 men with hemophilia A who had acquired hepatitis C through the use of plasma-derived clotting factor concentrates.
Patients were tested for factor VIII inhibitors before the start of interferon therapy and every 6 months thereafter.
21 patients with hemophilia A received interferon therapy for chronic hepatitis C infection for a mean of 19.5 months (range, 0.5 to 36 months). In 2 patients, inhibitors were detected on one occasion (maximum titer, 1.2 Bethesda units/mL) during interferon therapy. In 3 patients who were known to have had inhibitors before interferon therapy, no anamnestic reaction was seen during treatment. In 3 of 14 untreated controls who were followed for a mean of 28 months (range, 18 to 40 months), inhibitors were detected on one occasion (maximum titer, 2.3 Bethesda units/mL).
Long-term interferon therapy in patients with hemophilia did not increase the risk for development of factor VIII inhibitors.
Mauser-Bunschoten EP, Damen M, Reesink HW, et al. Formation of Antibodies to Factor VIII in Patients with Hemophilia A Who Are Treated with Interferon for Chronic Hepatitis C. Ann Intern Med. 1996;125:297–299. doi: 10.7326/0003-4819-125-4-199608150-00007
Download citation file:
Published: Ann Intern Med. 1996;125(4):297-299.
Coagulopathies, Gastroenterology/Hepatology, Hematology/Oncology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use